Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Blood (2025) 146 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2025-LBA-6

Published: 2025

Journal Articles

Single-cell sequencing of bone marrow cells and peripheral mononuclear cells reveals immune features of paraneoplastic pemphigus in a FL patient

Rong Wei, Shenmiao Yang, Jin Lu, Xiaojun Huang

Blood (2025) 146 (Supplement 1): 7114.

https://doi.org/10.1182/blood-2025-7114

Published: 2025

Journal Articles

Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in advanced solid tumors: A multicenter, randomized, double-blind, placebo-controlled phase III trial

Blood (2025) 146 (Supplement 1): 1256.

https://doi.org/10.1182/blood-2025-1256

Published: 2025

Journal Articles

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

Blood (2025) 146 (Supplement 1): 5812.

https://doi.org/10.1182/blood-2025-5812

Published: 2025

Journal Articles

The dynamic landscape of immune environment for MM patients receiving T cell redirectiing therapies

Haimeng Li, Xuelin Dou, Yang Liu, Guang Hu, Xiao-Dong Mo, Nan Peng, Lei Wen, Qian Li, Yue Wu, HuiXia Guo, Yijuan Chen, Liru Wang, Luyang Sun, Jin Lu

Blood (2025) 146 (Supplement 1): 7533.

https://doi.org/10.1182/blood-2025-7533

Published: 2025

Journal Articles

Health-related quality of life in Chinese multiple myeloma patients treated with daratumumab-based regimens in real world: Exploratory analysis of the MMY4032

Luqun Wang, Wei Yang, Yafei Wang, Ting Niu, Rong Fu, Yuping Zhong, Wenbin Qian, Kaiyang Ding, Kai Sun, Hong Liu, Baijun Fang, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Jin Lu

Blood (2025) 146 (Supplement 1): 7529.

https://doi.org/10.1182/blood-2025-7529

Published: 2025

Journal Articles

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Blood (2025) 146 (Supplement 1): 5819.

https://doi.org/10.1182/blood-2025-5819

Published: 2025

Journal Articles

A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 91.

https://doi.org/10.1182/blood-2025-91

Published: 2025

Journal Articles

Dara-vd vs vrd: A breakthrough in newly diagnosed multiple myeloma treatment — superior survival and safety profiles

Blood (2025) 146 (Supplement 1): 7583.

https://doi.org/10.1182/blood-2025-7583

Published: 2025

Journal Articles

Early dflc response for predicting complete hematological response in patients with AL amyloidosis: A multi-center prospective observational study

Yang Liu, Xianghuang Huang, Huasheng Liu, Liru Wang, Yanqiu Zhao, Yini Wang, Yuping Zhong, Aijun Liao, Aili Zhai, Jinzhou Guo, Huinan Jiang, Xiaojun Huang, Jin Lu

Blood (2025) 146 (Supplement 1): 7496.

https://doi.org/10.1182/blood-2025-7496

Published: 2025

Journal Articles

Pharmacokinetics, pharmacodynamics, and biomarkers of lbl-034, a GPRC5D-targeted T cell engager, in a first-in-human phase Ⅰ/Ⅱ study in relapsed/refractory multiple myeloma

Bin Fan, Juanjuan Wu, Jin Lu, Xuelin Dou, Wenduo He, Chengtao Lu, Ting Lv, Yilan Mei, Xiaoqiang Kang, Shengli Cai

Blood (2025) 146 (Supplement 1): 4070.

https://doi.org/10.1182/blood-2025-4070

Published: 2025

Journal Articles

Clinical Characteristics and Prognostic Analysis of Non-Amyloid Monoclonal Gammopathy of Renal Significance (MGRS) in China

Yuhang Song, Yang Liu, Junru Liu, Juan Li, Jin Lu, Junling Zhuang

Blood (2024) 144 (Supplement 1): 4679.

https://doi.org/10.1182/blood-2024-206458

Published: 2024

Journal Articles

The Race Against Time: Rapid Dflc Response in C1D7 Predicts Complete Hematologic Response in Systemic AL Amyloidosis

Yang Liu, Jingyi Bi, Ashley Mai, Nan Peng, Lei Wen, KaiYan Liu, Jin Lu

Blood (2024) 144 (Supplement 1): 6878.

https://doi.org/10.1182/blood-2024-203345

Published: 2024

Journal Articles

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2024-204620

Published: 2024

Journal Articles

Global Burden of Disease of Multiple Myeloma in China from 1990 to 2021

Guixiang Duan, Xuelin Dou, Yanting Zhong, Kai-Yan Liu, Jinlei Qi, Jin Lu, Maigeng Zhou

Blood (2024) 144 (Supplement 1): 6974.

https://doi.org/10.1182/blood-2024-205159

Published: 2024

Journal Articles

A Matched Comparison of Pola-R-CHP Vs. R-CHOP for DLBCL with Extranodal Involvement

Shenmiao Yang, Rong Wei, Yang Liu, Xuelin Dou, Lei Wen, Jin Lu, Fengrong Wang, Xiaodong Mo, Xiaojun Huang

Blood (2024) 144 (Supplement 1): 6478.

https://doi.org/10.1182/blood-2024-211660

Published: 2024

Journal Articles

Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Blood (2024) 144 (Supplement 1): 891.

https://doi.org/10.1182/blood-2024-205077

Published: 2024

Journal Articles

Clinical Features and Prognostic Nomogram for Therapy-Related Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Menglin Li, Yi-Meng Li, Qingyuan Qu, Yuxiu Chen, Jianying Zhou, Mengyu Xiao, Chencong Wang, Qi Chen, Xiaolu Zhu, Yun He, YuanYuan Zhang, Qian Jiang, Hao Jiang, Jin Lu, YingJun Chang, Xiaosu Zhao, Xiangyu Zhao, Xiao Jun Huang, Xiaohui Zhang

Blood (2024) 144 (Supplement 1): 1486.

https://doi.org/10.1182/blood-2024-204777

Published: 2024

Journal Articles

Real-World Clinical Outcomes of Daratumumab-Based Regimens in Chinese Patients with Multiple Myeloma By Cytogenetic Risk: A Subgroup Analysis of the MMY4032 Study

Luqun Wang, Wei Yang, Ting Niu, Yafei Wang, Rong Fu, Yuping Zhong, Kaiyang Ding, Kai Sun, Baijun Fang, Hong Liu, Wenbin Qian, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Canchan Cui, Jin Lu

Blood (2024) 144 (Supplement 1): 7874.

https://doi.org/10.1182/blood-2024-201134

Published: 2024

Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Blood (2024) 144 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2024-202893

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Single-cell sequencing of bone marrow cells and peripheral mononuclear cells reveals immune features of paraneoplastic pemphigus in a FL patient

Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in advanced solid tumors: A multicenter, randomized, double-blind, placebo-controlled phase III trial

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

The dynamic landscape of immune environment for MM patients receiving T cell redirectiing therapies

Health-related quality of life in Chinese multiple myeloma patients treated with daratumumab-based regimens in real world: Exploratory analysis of the MMY4032

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma

Dara-vd vs vrd: A breakthrough in newly diagnosed multiple myeloma treatment — superior survival and safety profiles

Early dflc response for predicting complete hematological response in patients with AL amyloidosis: A multi-center prospective observational study

Pharmacokinetics, pharmacodynamics, and biomarkers of lbl-034, a GPRC5D-targeted T cell engager, in a first-in-human phase Ⅰ/Ⅱ study in relapsed/refractory multiple myeloma

Clinical Characteristics and Prognostic Analysis of Non-Amyloid Monoclonal Gammopathy of Renal Significance (MGRS) in China

The Race Against Time: Rapid Dflc Response in C1D7 Predicts Complete Hematologic Response in Systemic AL Amyloidosis

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Global Burden of Disease of Multiple Myeloma in China from 1990 to 2021

A Matched Comparison of Pola-R-CHP Vs. R-CHOP for DLBCL with Extranodal Involvement

Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Clinical Features and Prognostic Nomogram for Therapy-Related Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Real-World Clinical Outcomes of Daratumumab-Based Regimens in Chinese Patients with Multiple Myeloma By Cytogenetic Risk: A Subgroup Analysis of the MMY4032 Study

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only